Intelligence · Clinical Development
Pipeline search results
Programs matching “rivaroxaban” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 14 pipeline programs matching "rivaroxaban" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
D9604C00001
AstraZeneca AB
Reversal of anticoagulation effect in patients on a FXa inhibitor (apixaban, rivaroxaban, or edoxaban) who require urgent surgery or procedure, and who have a major risk of bleeding.
1 trial -
Rivaroxaban
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Atrial Fibrillation
1 trial -
Rivaroxaban (Xarelto, BAY59-7939)
Bayer HealthCare AG
Pulmonary Embolism
1 trial -
Rivaroxaban (Xarelto, BAY59-7939)
Bayer HealthCare AG
Venous Thromboembolism
2 trials -
Rivaroxaban (Xarelto, BAY59-7939)
Bayer HealthCare AG
Prevention & Control
1 trial -
Rivaroxaban 2.5 Mg Oral Tablet
The George Institute
Chronic Kidney Diseases
1 trial -
Rivaroxaban 2.5 mg
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Acute Coronary Syndrome
1 trial -
Heparin and Rivaroxaban
The First People's Hospital of Lianyungang
Liver Cirrhosis
1 trial -
Aspirin + Clopidogrel + Rivaroxaban
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Coronary Artery Disease
1 trial -
Rivaroxaban 2.5 MG Oral Tablet [Xarelto]
The University of Hong Kong
Atherosclerosis, Coronary
1 trial -
Rivaroxaban 2.5 mg
Second Xiangya Hospital of Central South University
Acute Coronary Syndrome
1 trial -
low-dose rivaroxaban
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Atrial Fibrillation
1 trial -
Rivaroxaban
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Liver Cirrhosis
1 trial -
Rivaroxaban
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Ventricular Mural Thrombosis
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.